Latest News

Big multiple sclerosis breakthrough: Phase 1 trial safely resets patients' immune systems and reduces attack on myelin protein

A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients' immune systems' reactivity to myelin by 50 to 75 percent. The therapy used billions of patients' own specially processed blood cells to create tolerance to myelin, the insulating layer that forms around nerves. In MS, the immune system attacks myelin. The approach left the normal immune system intact.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Humiliation tops list of mistreatment toward med students

  • Researchers examine effectiveness of blocking nerve to help with weight loss

  • Economic success drives language extinction

  • Mouse model provides window into working brain

  • Plain cigarette packs don't hurt small retailers or boost trade in illicit tobacco

  • High dietary salt may worsen multiple sclerosis symptoms

  • How Alzheimer's peptides shut down cellular powerhouses

  • Real tremors, or drug-seeking patient? New app can tell

  • Memory and Alzheimer's: Towards a better comprehension of the dynamic mechanisms

  • Nucleotide change could initiate Fragile X Syndrome

  •